NSD2 and colon adenocarcinoma: Furthermore, in patients with mutations of a CR set (EP300, MSH6, NSD2 and TRRAP), COAD patients with MAP2 low expression showed better prognosis and could benefit more from Paclitaxel and Docetaxel.